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Abstract Decreased tongue strength (TS) might herald
bulbar involvement in patients with amyotrophic lateral
sclerosis (ALS) well before dysarthria or dysphagia occur,
and as such might be prognostic of short survival. The
purpose of this study was to investigate the prognostic
value of a decreased TS, in addition to other prognostic
factors, such as site of onset, bulbar symptoms, bulbar
signs, age, sex, maximum phonation time, time from
symptoms to diagnosis, and gastrostomy, for survival time
in patients with ALS. TS was measured in four directions
in 111 patients who attended the diagnostic outpatient
motor neuron clinic of our university hospital. Of these
patients, 54 were diagnosed with ALS. TS was considered
abnormal if the strength in minimally one direction was at
least two standard deviations below the reference values
obtained from comparable age category and sex-groups of
healthy controls (n = 119). Twenty of the patients with
ALS had a decreased TS. Multivariable analysis showed
that, in addition to age, TS was an independent prognostic
factor for survival time in patients with ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive dis-
order caused by degeneration of both upper (UMN) and
lower (LMN) motor neurons in the bulbar and spinal
regions. The cause of ALS is not known and to date there is
no curative treatment. Knowledge of disease progression
and survival time is of utmost importance for clinical care
and research. The mean survival time is 3–5 years,
although a small minority of patients (7 %) may survive for
10 years or longer [1, 6, 7, 15, 27]. Several prognostic
factors for survival have been identified, such as age at
diagnosis or onset, time between first symptoms and first
examination, and site of symptom onset [6, 9, 11].
Survival is worse in patients with bulbar-onset ALS as
compared with spinal-onset ALS [6, 27, 28]. Moreover,
survival is significantly shorter in patients with bulbar
involvement at first assessment independent of the site of
onset [11, 27]. However, the strength of the association
between bulbar involvement and survival time might be
influenced by the way bulbar involvement is defined. Until
now, most studies have described bulbar involvement as
the presence of symptoms or signs of dysarthria or dys-
phagia. While studies have used questionnaires [7] and
quantitative bulbar measurements [2, 12, 18, 19, 21] to
describe bulbar changes, as far as we know an objective
noninvasive quantitative measure of bulbar involvement
has not been used to predict survival in ALS.
Tongue strength (TS) has been found to be a reliable
indicator of bulbar involvement in various diseases [3, 13,
17, 20, 22, 24, 26] and in animal models of ALS [8].
Reduced TS in ALS might be caused by both UMN and
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LMN degeneration and can occur in patients with and
without clinical symptoms of dysarthria or dysphagia [12,
19]. Bulbar muscle weakness in ALS is usually more
pronounced in the muscles of the tongue than in muscles of
the lips and jaw [12, 19]. The reason for this is not known
but might be due to anterograde degeneration and the rel-
atively large representation of the tongue in the primary
motor cortex. Another possible explanation is that the
motor units of the tongue function near their maximum
firing rate under normal conditions, so compensatory
additional activation might not be possible [21].
In the present study, we prospectively studied the
prognostic value of a decreased TS compared to other
known prognostic factors for survival in ALS. TS was




All patients who were referred to the diagnostic outpatient
motor neuron clinic of the Radboud University Medical
Centre (Nijmegen, the Netherlands) between October 2003
and June 2007 were eligible (n = 111). Referral was based
on the medical suspicion of some form of motor neuron
disease. Patients were included prospectively provided that
a TS measurement could be performed on the same day as
the neurological examination and the diagnostic electro-
myography (EMG) investigation. An experienced neurol-
ogist (HJS) diagnosed the patients and determined the site
of disease onset on the basis of the first symptoms. TS was
measured by an experienced speech and language therapist
(JW). The maximum phonation time (MPT) was measured
to estimate vital capacity [11, 16], because with this
measurement it is also possible to assess voice quality. On
a single breath, patients were instructed to say /a:/ for as
long as possible. This procedure was repeated three times
and the maximum sustained phonation time was used for
analysis. The following data were recorded at time of the
initial assessment: age, sex, site of onset, bulbar symptoms,
bulbar signs, MPT, and TS.
Only patients with ALS [4] (‘possible’, ‘probable lab-
oratory supported’, ‘probable’, or ‘definite’ according to
the revised El Escorial criteria) at initial diagnosis or
during follow-up were included in this study (n = 54). All
patients were under the care of multidisciplinary rehabili-
tation teams specialized in ALS. Time from symptoms to
diagnosis, date of gastrostomy placement, and time to
death (if applicable) were collected during follow-up.
When necessary, survival status and gastrostomy place-
ment were determined by telephone calls.
Over the same time period, 119 healthy volunteers (aged
14–85 years) were asked to participate to obtain normal
reference values for TS [25], with careful dividing into
three age categories and sex groups (20 persons per group).
The volunteers were recruited in the academic medical
center (colleagues and partners of patients), from the per-
sonal environment (relatives and acquaintances), and after
advertising at swimming and bowling centers. Exclusion
criteria were a history of a neurological disease, other
diseases that might cause decreased oropharyngeal strength
(e.g., severe diabetes mellitus, chronic obstructive pul-
monary disease, or otolaryngologic problems), the absence
of teeth, and poorly fitting dentures.
The local ethics committee approved the study and all
participants provided informed consent.
Tongue strength
Transducer
The TS transducer used (Fig. 1a) was developed on the
basis of an earlier model [23, 26]. It consisted of a lever on
which four strain gauges were arranged in a Wheatstone
bridge configuration. The device was positioned between
the teeth, and the tongue was placed in a cup at the end of
the lever, and measurements in cranial, lateral, and frontal
directions were taken, involving intrinsic as well as
extrinsic tongue muscles. The left and right parts of the
mouthpiece of the transducer were covered with
Fig. 1 a Tongue strength measurement device. b The tongue strength
measurement device in use
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impression material for stability and to ensure that the
device was placed in the same position in the mouth of
each participant at each measurement. The TS transducer
was calibrated several times and values remained stable
during the study period.
Measurement
All participants were assessed in the same way. Before the
first measurements, they were carefully instructed and
guided through several practice trials. Participants were
seated on a normal chair and were asked to put the
mouthpiece of the device in their mouth, to hold the bite
fixation parts between their teeth, and to push the tongue
against the transducer in the different directions (Fig. 1b).
Once we had established that they understood the task to be
performed, they were requested to push as hard as possible
in a specific direction for *5 s. This was repeated for
every direction: upward, frontal, left, and right. One set of
four directions was followed by a rest period of 30 s, to
allow the muscles to relax. Then three other sets of mea-
surements were taken, with a balanced sequence of the four
force directions to exclude a direction effect due to fatigue.
The mean values of the four sets in each direction were
used as a measure of TS.
Statistical methods
A TS score in at least one of the four directions of two
standard deviations (SD) below the mean of the age- and
sex-specific healthy reference group was considered
abnormal. Fisher’s exact test was used to test differences
between patients with and without an abnormal TS for
statistical significance in the case of nominal variables
(onset site, bulbar symptoms, bulbar signs, sex, gastros-
tomy, MPT) and Mann–Whitney U in the case of contin-
uous variables (age and time from symptoms to diagnosis).
For MPT, patients were allocated to two groups (MPT
B10, MPT [10 s), because this threshold was found to be
of clinical relevance [16].
Time from diagnosis to death was the primary outcome.
The end-of-study date (August 1, 2011) was used for sur-
viving patients and the date of last contact for the one
patient who was lost to follow-up. Kaplan–Meier estimates
are presented. The log rank test was used to test differences
between the two TS groups with regard to time to death.
Univariable proportional hazard model was used to test
the differences in survival for each independent variable
separately (onset site, bulbar symptoms, bulbar signs, age,
sex, MPT, TS, time from symptoms to diagnosis, and
gastrostomy). The dependent variable was time to death.
Crude hazard ratios (HR) with 95 % confidence interval
(CI) are presented. A multivariable proportional hazard
model was used with selection procedures to study the
independent contribution of a decreased TS. The dependent
variable was time to death. All variables in the univariable
model with a p \ 0.10 were valid for selection: TS, age,
and onset site. The adjusted HR with 95 % CI of the final
model are presented.
All statistical analyses were performed using SPSS,
version 16.0 for windows (SPSS, Chicago, IL, USA).
Results
Fifty-four of the 111 eligible patients were diagnosed with
ALS and included in this study (25 males, age 20–76 years;
29 females age 45–80 years). The clinical and demographic
characteristics of these patients are presented in Table 1.
Twenty patients (37 %) had an abnormal TS. Of these,
13 patients (65 %) had a bulbar onset and 13 patients
(65 %) were female. Gastrostomy was performed in 26 of
the 54 patients (48 %) and in 12 (60 %) of the patients with
an abnormal TS. The site of onset, the presence of bulbar
symptoms, and bulbar signs were significant differences
between patients with and without an abnormal TS.
Table 1 Clinical and
demographic characteristics of
the 54 patients with
amyotrophic lateral sclerosis
a maximum phonation time in
abnormal n = 17, normal
n = 29
p Fisher’s exact test (*) and test
of Mann–Whitney (**)
Tongue strength p
Abnormal (n = 20)
median (range)/ n (%)
Normal (n = 34)
median (range)/ n (%)
Sex (male) 7 (35) 18 (51) 0.26*
Onset site (bulbar) 13 (65) 6 (18) \0.00*
Bulbar symptoms (presence) 17 (85) 9 (32) \0.00*
Bulbar signs (presence) 15 (75) 5 (15) \0.00*
Gastrostomy (presence) 12 (60) 14 (41) 0.09*
MPT (\10 sec)a 6 (35) 5 (17) 0.28*
Age at diagnosis (year) 66.0 (20.0–80.0) 63.5 (40.0–79.0) 0.52**
Time from symptoms to
diagnosis (month)
12.0 (6.0–60.0) 10.0 (4.0–60.0) 0.70**
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Forty-five patients died during the study, 8 patients were
still alive at the end of the study (one of whom had an
abnormal TS at diagnosis), and 1 patient was lost to fol-
low-up.
The reference group of healthy volunteers consisted of 58
men and 61 women aged 14–85 years. Table 2 shows the
age- and sex-specific reference values for TS in the left
direction and the cut-off values (i.e., age and sex specific
means -2 SDs). Reference values for the other directions
(right, cranial, and frontal) are available from the first author.
Kaplan–Meier estimates of time to death in patients with an
abnormal and normal TS are shown in Fig. 2 and those in
patients younger and older than 69 years are shown in Fig. 3.
Table 3 shows the crude HR (95 % CI) for time to death
using univariable proportional hazard model. A statistically
significant shorter survival time was associated with an
abnormal TS, bulbar onset, and older age. Table 3 also
shows the adjusted HR (95 % CI) for time to death of the final
multivariable proportional hazard model with a forward
selection procedure. Age and TS were significantly and
independently associated with time to death; site of onset
was not selected because of the strong correlation with TS.
Discussion
In this prospective study of newly diagnosed patients with
ALS, an abnormal TS and age were prognostic factors for
survival time independent of sex, presence of bulbar
symptoms or signs, baseline MPT (regarded as an estima-
tion of vital capacity [11, 16]), time from symptom onset to
diagnosis, and time to gastrostomy placement. Bulbar onset
was also associated with a poor survival, as reported pre-
viously [6]. However, a weak TS was associated with a
poor survival regardless of the site of ALS symptom onset.
Furthermore, a reduced TS at presentation is of more
prognostic value than the presence of bulbar symptoms or
signs. Thus, this independent non-invasive prognostic
variable might be useful to stratify patients in studies with
survival as primary outcome [10]. Information concerning
survival is essential to these patients. In addition, knowl-
edge that the bulbar muscles are weak might prompt a
multidisciplinary ALS team to consult a speech and lan-
guage therapist and a dietician, in order to prevent prob-
lems due to dysphagia. In contrast, disease progression will
probably be slower in patients with dysarthria but a rela-
tively normal TS, which would give the patient and the
team time to make plans.
The relatively poor survival of patients with an abnor-
mal TS might be because these patients are more likely to
develop dysphagia, which may give rise to malnutrition,
aspiration, and pulmonary infections, or because an
abnormal TS in patients with spinal onset might reflect a
spreading pattern of LMN involvement, which is associ-
ated with a faster progression [14].
The median age (64 years), age range (20–80 years),
and onset distribution in our study population were similar
to those reported in large demographic studies of ALS.
This may support the external validity of our findings [7,
11, 27]. However, the survival time was longer in our study
than in population-based studies, which may be because
our study was conducted in a tertiary care center [5]. In this
study the percentage of women is higher than in most other
studies. However, multivariable analyses with selection
procedure for men and for women, separately, showed that,
as expected, TS is of similar importance for the prediction
of survival in men and in women. Note that TS is already
corrected for sex and age.
Table 2 Mean, (SD) and cut-off value of the TS in the left direction
for the healthy volunteers categorized by sex, by age
Age
(years)
TS (Newton) in male TS (Newton) in female
n mean (SD) Cut-
off
valuea
n mean (SD) Cut-
off
valuea
14–40 23 8.01 (2.01) 3.99 24 5.48 (1.37) 2.74
41–60 16 6.53 (1.78) 2.97 17 5.04 (1.35) 2.34
61–85 19 4.47 (1.38) 1.71 20 4.49 (1.16) 2.17
a The cut-off value for abnormality is the mean value -2 SDs
SD standard deviation, TS tongue strength
Fig. 2 Kaplan–Meier estimates for time to death in patients with a
normal tongue strength (TS; solid line) or an abnormal TS (broken
line). Vertical bars indicate censured data. The p value for differences
between TS groups was 0.01 using the log rank test
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The TS measurement device was made in our labora-
tory, and as it was carefully calibrated, we see no reason
why results would be different with another calibrated
device.
In conclusion, a decreased TS at the time of diagnosis is
an important independent prognostic factor for survival in
patients with ALS. Objective measurement of TS can be
used to assess early bulbar involvement in clinical care.
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